A Single-Dose, Open-Label, Randomized, Crossover Dose Proportionality Study to Evaluate the Effect of Dose on the Pharmacokinetics of 8, 16, 32 and 64 mg OROS Hydromorphone Under Fasted Conditions in Healthy Adult Taiwanese Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Plasma hydromorphone concentrations
研究概览
简要总结
The purpose of this study is to evaluate the pharmacokinetics of OROS Hydromorphone in healthy adult Taiwanese participants after oral administration of 4 different dose strengths of 8, 16, 32 and 64 mg under fasted conditions.
详细描述
This is a single-center, randomized (study drug assigned by chance like flipping a coin), open-label (all people involved know the identity of the intervention), 4-way crossover (participants receive different interventions sequentially during the trial) study in healthy adult Taiwanese participants. All participants will be randomly assigned to 1 of the 4 different possible treatment sequences and will receive all treatments in the order specified by the randomization schedule. The study consists of a screening phase, an open-label treatment phase consisting of 4 single-dose treatment periods, and end-of-study or withdrawal assessments. During the open-label treatment periods, the participants will stay in the center until completion of the 72-hour pharmacokinetics [PK] (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time) blood sample on Day 4. A 7- to 14-day washout period (period when receiving no treatment) will separate the open-label treatment periods. The safety and tolerability will be evaluated over the investigated dose range. The duration of participation in the study for an individual participant will be approximately 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body mass index (BMI) between 18 and 25 kg/m², inclusive and a body weight of not less than 50 kg - Participants must utilize a medically acceptable method of contraception throughout the entire study period and for 1 month after the study is completed - Each participant will receive a naloxone challenge test for opioid dependency at screening. Only those participants who pass this challenge test will be allowed to continue in the study
排除标准
- •History of or current clinically medical illness or any other condition that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results - Clinically significant abnormal values for hematology, clinical chemistry or urinalysis - Clinically significant abnormal physical examination, vital signs or 12 lead electrocardiogram (ECG) - Use of certain prescription or nonprescription medication, and consumption of products that may interfere with the study
研究组 & 干预措施
Sequence 1: Treatment A-D-B-C
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment A: Hydromorphone 8 mg (Drug)
Sequence 1: Treatment A-D-B-C
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment B: Hydromorphone 16 mg (Drug)
Sequence 1: Treatment A-D-B-C
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment C: Hydromorphone 32 mg (Drug)
Sequence 1: Treatment A-D-B-C
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment D: Hydromorphone 64 mg (Drug)
Sequence 2: Treatment B-A-C-D
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment A: Hydromorphone 8 mg (Drug)
Sequence 2: Treatment B-A-C-D
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment B: Hydromorphone 16 mg (Drug)
Sequence 2: Treatment B-A-C-D
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment C: Hydromorphone 32 mg (Drug)
Sequence 2: Treatment B-A-C-D
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment D: Hydromorphone 64 mg (Drug)
Sequence 3: Treatment C-B-D-A
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment A: Hydromorphone 8 mg (Drug)
Sequence 3: Treatment C-B-D-A
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment B: Hydromorphone 16 mg (Drug)
Sequence 3: Treatment C-B-D-A
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment C: Hydromorphone 32 mg (Drug)
Sequence 3: Treatment C-B-D-A
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment D: Hydromorphone 64 mg (Drug)
Sequence 4: Treatment D-C-A-B
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment A: Hydromorphone 8 mg (Drug)
Sequence 4: Treatment D-C-A-B
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment B: Hydromorphone 16 mg (Drug)
Sequence 4: Treatment D-C-A-B
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment C: Hydromorphone 32 mg (Drug)
Sequence 4: Treatment D-C-A-B
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
干预措施: Treatment D: Hydromorphone 64 mg (Drug)
结局指标
主要结局
Plasma hydromorphone concentrations
时间窗: 20 time points up to 72 hours post-dose
Sequential blood samples are collected over 72 hours during each treatment period. The study has a total of four 5-day treatment periods. The treatment periods are separated by a 7- to 14-day washout period.
次要结局
- Number of participants with adverse events as a measure of safety and tolerability(Approximately 12 weeks)